Reviewing Stoke Therapeutics (NASDAQ:STOK) and MeiraGTx (NASDAQ:MGTX)

Stoke Therapeutics (NASDAQ:STOK) and MeiraGTx (NASDAQ:MGTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Stoke Therapeutics and MeiraGTx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stoke Therapeutics	-753.60%	-59.36%	-51.46%
MeiraGTx	19.87%	283.85%	29.39%

Earnings & Valuation

This table compares Stoke Therapeutics and MeiraGTx”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stoke Therapeutics	$184.42 million	8.46	-$6.89 million	($3.34)	-7.24
MeiraGTx	$81.39 million	10.95	-$114.20 million	$0.71	13.07

Stoke Therapeutics has higher revenue and earnings than MeiraGTx. Stoke Therapeutics is trading at a lower price-to-earnings ratio than MeiraGTx, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.5% of MeiraGTx shares are owned by institutional investors. 9.6% of Stoke Therapeutics shares are owned by insiders. Comparatively, 7.4% of MeiraGTx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Stoke Therapeutics and MeiraGTx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stoke Therapeutics	1	0	10	0	2.82
MeiraGTx	0	3	5	1	2.78

Stoke Therapeutics currently has a consensus price target of $44.25, indicating a potential upside of 83.08%. MeiraGTx has a consensus price target of $24.71, indicating a potential upside of 166.32%. Given MeiraGTx’s higher probable upside, analysts clearly believe MeiraGTx is more favorable than Stoke Therapeutics.

Volatility and Risk

Stoke Therapeutics has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500.

Summary

MeiraGTx beats Stoke Therapeutics on 10 of the 15 factors compared between the two stocks.

About Stoke Therapeutics

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

About MeiraGTx

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.